Figure 4
miR-144 reduced the expression of its target genes CAV2 and FGF7. (a,b) Sequence of the 3′ UTR of CAV2 and FGF7 matched with the recognition site of miR-144. The seed sequence was marked in red color. (c,d) pGL3-promoter vector bearing the wild type 3′ UTRs of CAV2 and FGF7 (gray box), the mutant 3′ UTR fragments (black box) or the vehicle (white box) were co-transfected with miR-144 mimic or Scramble (c), or with miR-144 ASO or Scramble (d) respectively. The luciferase activity was detected 48 h later (n = 5). (e,f) U251 cells were transfected with miR-144 mimic (e) or miR-144 inhibitor (f) and mRNA levels of CAV2 and FGF7 were detected (n = 4). (g,h) U251 cells were treated as same as (e,f) and the protein levels of CAV2 and FGF7 were determined (n = 4). (i,j) The correlation of miR-144 with glioma patient survival time in TCGA database. (k,l) The expression of CAV2 and FGF7 was evaluated in normal brain tissue (n = 12) and glioma tissue (n = 24). (m,n) The expression levels of miR-144 and its targets were determined and analyzed in brain tissues of 43 glioma patients and 17 traumatic brain injury patients. Bars represent means ± SD, *P < 0.05, **P < 0.01, ***P < 0.001.
